Divi's Laboratories Ltd
NSE:DIVISLAB
Intrinsic Value
Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. [ Read More ]
The intrinsic value of one
DIVISLAB
stock under the Base Case scenario is
2 173.75
INR.
Compared to the current market price of 3 994.05 INR,
Divi's Laboratories Ltd
is
Overvalued by 46%.
Divi's Laboratories Ltd's market capitalization is 1.1T INR.
DIVISLAB stock price is 3 994.05 INR.
DIVISLAB stock (2 173.75 INR) is 46% less than its price (3994.05 INR).
DIVISLAB stock (900.51 INR) is 77% less than its price (3994.05 INR). Open DCF Valuation
DIVISLAB stock (3 447 INR) is 14% less than its price (3994.05 INR). Open Relative Valuation
DIVISLAB has downside potential of 17% compared to the average analyst price target.
Open Wall St Estimates
DIVISLAB's ROE (Return on Equity) for the past 12 months is positive and is equal to 11%.
DIVISLAB's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 12%.
DIVISLAB's Revenue has been growing by 4% per year for the last 3 years.
DIVISLAB's Revenue has dropped by 10% over the past 12 months.
DIVISLAB's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
DIVISLAB's ROE (Return on Equity) has significantly decreased in the last 3 years from 24% to 11%.
DIVISLAB's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 26% to 12%.
DIVISLAB has positive Net Income for the last twelve months.
DIVISLAB has positive three-year average ROE (Return on Equity): 22%. The company is efficient at transforming stockholders' equity into net income.
DIVISLAB has positive Operating Income for the last twelve months.
DIVISLAB has positive three-year average ROIC (Return on Invested Capital): 24%. The company is efficient at using invested capital to generate operating income.
DIVISLAB has positive Free Cash Flow for the last twelve months.
DIVISLAB has positive Gross Profit for the last twelve months.
DIVISLAB's D/E (Debt to Equity) is very low and is equal to 0.
DIVISLAB's short-term assets (89B INR) exceed its short-term liabilties (10B INR).
DIVISLAB's long-term assets (143B INR) exceed its long-term liabilties (16B INR).
DIVISLAB has negative Net Debt. This means that the company has more cash and short-term investments (36B INR) than debt (40m INR).
DIVISLAB's Altman Z-Score is very high and is equal to 41.21.
DIVISLAB earns more than enough operating income (16B INR) to safely cover interest payments on its debt (12m INR).
Valuation Backtest
Divi's Laboratories Ltd
Run backtest to discover the historical profit from buying and selling
DIVISLAB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Divi's Laboratories Ltd
Balance Sheet Decomposition
Divi's Laboratories Ltd
| Current Assets | 88.8B |
| Cash & Short-Term Investments | 36.2B |
| Receivables | 19.9B |
| Other Current Assets | 32.8B |
| Non-Current Assets | 54B |
| Long-Term Investments | 1.4B |
| PP&E | 51.5B |
| Intangibles | 30m |
| Other Non-Current Assets | 1.1B |
| Current Liabilities | 10.1B |
| Accounts Payable | 7.9B |
| Short-Term Debt | 20m |
| Other Current Liabilities | 2.2B |
| Non-Current Liabilities | 6B |
| Long-Term Debt | 20m |
| Other Non-Current Liabilities | 5.9B |
Earnings Waterfall
Divi's Laboratories Ltd
|
Revenue
|
74.9B
INR
|
|
Cost of Revenue
|
-30.5B
INR
|
|
Gross Profit
|
44.4B
INR
|
|
Operating Expenses
|
-28.4B
INR
|
|
Operating Income
|
15.9B
INR
|
|
Other Expenses
|
-2.1B
INR
|
|
Net Income
|
13.8B
INR
|
Free Cash Flow Analysis
Divi's Laboratories Ltd
DIVISLAB Profitability Score
Profitability Due Diligence
Divi's Laboratories Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Divi's Laboratories Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
DIVISLAB Solvency Score
Solvency Due Diligence
Divi's Laboratories Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Divi's Laboratories Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DIVISLAB Price Targets Summary
Divi's Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for
DIVISLAB
is 3 330.66 INR
with a low forecast of 2 566.41 INR and a high forecast of 4 396.35 INR.
Shareholder Return
DIVISLAB Price
Divi's Laboratories Ltd
| Average Annual Return | 28.58% |
| Standard Deviation of Annual Returns | 59.92% |
| Max Drawdown | -48% |
| Market Capitalization | 1.1T INR |
| Shares Outstanding | 265 468 579 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Divi's Laboratories Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 16,543 full-time employees. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).
Contact
IPO
Employees
Officers
The intrinsic value of one
DIVISLAB
stock under the Base Case scenario is
2 173.75
INR.
Compared to the current market price of 3 994.05 INR,
Divi's Laboratories Ltd
is
Overvalued by 46%.
You don't have any saved screeners yet
